Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Myasthenia Gravis × Sodium Chloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 10 Neoplasms 5 Carcinoma, Non-Small-Cell Lung 4 Pain, Postoperative 3 Melanoma 3 Leukemia, Myeloid, Acute 3 Brain Neoplasms 3 Recurrence 2 Ovarian Neoplasms 2 Hemorrhage 2 Chronic Pain 2 Agnosia 2 Vulvodynia 1 Uterine Cervical Neoplasms 1 Stomatitis 1 Stomach Neoplasms 1 Spinal Cord Neoplasms 1 Small Cell Lung Carcinoma 1 Skin Neoplasms 1 Seizures 1 Radiodermatitis 1 Radiation Injuries 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Postoperative Complications 1 Peripheral Nervous System Diseases 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Parathyroid Neoplasms 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1 Pain, Intractable 1

Interventions

rozanolixizumab 6 zilucoplan 5 efgartigimod alfa 5 eculizumab 4 telitacicept 3 Tacrolimus 3 Amifampridine 3 ravulizumab 2 Rituximab 2 Prednisone 2 HBM9161 2 satralizumab 1 remibrutinib 1 iptacopan 1 inebilizumab 1 Thymectomy 1 Sugars 1 Steroids 1 Sodium Chloride 1 Pyridostigmine Bromide 1 Prednisolone 1 Mycophenolic Acid 1 Leflunomide 1 Hizentra 1 Cladribine 1 Azathioprine 1 Alkalies 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02950155 2024-10-26

Rinomax

Karolinska Institutet

Phase 3 Completed

47 enrolled 24 charts

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡